5-Aminobenzimidazole is a heterocyclic compound that has been studied for its potential biological activity. It has been shown to have antibacterial, antifungal, and anticancer properties. The compound is synthesized through various methods, including the reaction of o-phenylenediamine with formic acid. Its importance lies in its potential as a building block for the synthesis of other bioactive compounds. The study of 5-aminobenzimidazole is driven by its potential therapeutic applications and its ability to interact with various biological targets.'
5-aminobenzimidazole: RN given refers to parent cpd; structure given in first source; inhibits gastric secretions in rats [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 13623 |
| CHEMBL ID | 1617811 |
| SCHEMBL ID | 115965 |
| MeSH ID | M0164497 |
| Synonym |
|---|
| AC-2803 |
| 5-aminobenzimidazole dihydrochloride |
| BB 0217003 |
| F2158-1066 |
| 1h-benzoimidazol-5-ylamine |
| nsc-231612 |
| 934-22-5 |
| 6-aminobenzimidazole |
| benzimidazole, 5-amino- |
| nsc231612 |
| 5-aminobenzimidazole |
| 55299-95-1 |
| benzimidazole, 6-amino- |
| einecs 213-279-0 |
| benzimidazol-5-ylamine |
| nsc 231612 |
| 1h-benzimidazol-5-amine |
| OPREA1_342288 |
| AH-034/32844026 |
| 1h-benzimidazol-5-ylamine |
| OPREA1_610116 |
| AKOS000111798 |
| 3h-benzimidazol-5-amine |
| FT-0655568 |
| AKOS003574217 |
| NCGC00184564-01 |
| NCGC00184564-02 |
| 1h-benzimidazol-6-amine |
| STK731665 |
| unii-7l7289019s |
| 7l7289019s , |
| 1h-1,3-benzodiazol-6-amine |
| 1h-benzo[d]imidazol-5-amine |
| 3h-benzoimidazol-5-ylamine |
| BBL011727 |
| PS-4509 |
| 1h-1,3-benzimidazol-5-amine |
| 1h-1,3-benzodiazol-5-amine |
| benzimidazole, 5(or 6)-amino- |
| benzimidazol-5-amine |
| aminobenzimidazole, 5- |
| 3h-benzo(d)imidazol-5-amine |
| 3h-benzo[d]imidazol-5-amine |
| FT-0620009 |
| 5-amino-1h-benzo[d]imidazole |
| 5-amino-benzimidazole |
| 5-aminobenzimdazole |
| 5-aminobenzimidazol |
| 5-amino benzimidazole |
| 3h-benzimidazol-5-ylamine |
| 1h-benzimidazole-6-amine |
| 1h-benzoimidazol-5-amine |
| (1h-benzimidazol-5yl) amine |
| SCHEMBL115965 |
| bdbm50455561 |
| chembl1617811 , |
| benzimidazolamine |
| mfcd00831692 |
| SY002960 |
| 2P-043 |
| 5-amino-1h-benzimidazole |
| 1h-benzo[d]imidazol-6-amine |
| 1h-benzimidazol-6-amine # |
| 5-amino-1h-benzoimidazole |
| CS-0096864 |
| J-519689 |
| 5-aminobenzimidazole, aldrichcpr |
| 6-aminobenzimidazole, 95% |
| DTXSID70239406 |
| mfcd00465258 |
| Z1741960823 |
| 1h-1,3-benzodiazol-5-amine hydrochloride |
| F11742 |
| BCP11467 |
| AMY3030 |
| Q27268505 |
| 1h-benzimidazol-5-amine dihydrochloride |
| EN300-57442 |
| 1h-1 pound not3-benzimidazol-5-amine |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 2.8184 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| Smad3 | Homo sapiens (human) | Potency | 14.1254 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 35.4813 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 70.7946 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Protein kinase C iota type | Homo sapiens (human) | IC50 (µMol) | 728.0000 | 0.0001 | 2.0378 | 10.0000 | AID1375384 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protein kinase activity | Protein kinase C iota type | Homo sapiens (human) |
| protein serine/threonine kinase activity | Protein kinase C iota type | Homo sapiens (human) |
| diacylglycerol-dependent serine/threonine kinase activity | Protein kinase C iota type | Homo sapiens (human) |
| protein binding | Protein kinase C iota type | Homo sapiens (human) |
| ATP binding | Protein kinase C iota type | Homo sapiens (human) |
| phospholipid binding | Protein kinase C iota type | Homo sapiens (human) |
| metal ion binding | Protein kinase C iota type | Homo sapiens (human) |
| protein serine kinase activity | Protein kinase C iota type | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1375384 | Inhibition of full-length N-terminal GST-fused human PKC-iota expressed in baculovirus expression system using (5FAM) RFARKGSLRQKNV as substrate after 60 mins by caliper assay | 2018 | Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10 | Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.96) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||